Meeting Banner
Abstract #0143

Breast tumour response to PEGPH20-induced stromal modulation assessed by multiparametric MRI

Emma L. Reeves1, Jin Li1, Jessica K. R. Boult1, Barbara Blouw2, David Kang2, Jeffrey C. Bamber1, Yann Jamin1, and Simon P. Robinson1
1Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom, 2Halozyme Therapeutics, San Diego, CA, United States

Degradation of hyaluronan by PEGPH20 can improve stromal-dense tumour response to therapy. Given PEGPH20 treatment is associated with a reduction in tumour water content, we hypothesised that T1, T2, MTR and ADC may inform on PEGPH20 response. MRI was performed before and after PEGPH20 treatment in 4T1 HAS3 and MDA-MB-231 LM2-4 orthotopic breast tumours. T1, T2, and ADC significantly decreased, and MTR significantly increased following PEGPH20 treatment in 4T1 HAS3 tumours. PEGPH20 significantly decreased ADC but did not change T1, T2 or MTR in MDA-MB-231 LM2-4 tumours. These data suggest that ADC can detect breast tumour response to PEGPH20.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here